Journal article
Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study
The Gambian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2–59 months by around 55%. Further surveillance is needed to ascertain the maximum effect of the vaccine in the 2–4 years and older age groups, and to monitor serotype replacement. Low-income and middle-income countries that introduce PCV13 can expect substantial reductions in invasive pneumococcal disease.
Authors
- Grant A. Mackenzie
- Bernard Ebruke
- Readon C. Ideh
- Bankole Kuti
- Peter Githua
- Emmanuel Olutunde
- Ogochukwu Ofordile
- Edward Green
- Effua Usuf
- Aliu Akano
- Ian Plumb
- Debasish Saha
- David Ameh
- Malick Ndiaye
- Oyedeji Adeyemi
- Jayani Pathirana
- Yekini Olatunji
- Bade Abatan
- Bilquees S. Muhammad
- Augustin E. Fombah
- Henry Badji
- Usman N. A. Ikumapayi
- Orin S. Levine
- Stephen R. Howie
- Richard A Adegbola
- Brian M. Greenwood
- Tumani Corrah
- Philip C. Hill
- David J. Jeffries
- Ilias Hossain
- Maria Knoll
- Kim Mulholland
- Momodou Jasseh
- Ahmad Manjang
- Rasheed Salaudeen
- E. David Nsekpong
- Sheikh Jarju
- Martin Antonio
- Sana Sambou
- Lamin Ceesay
- Yamundow Lowe-Jallow
- Uchendu Uchendu
Languages
- English
Publication year
2016
Journal
The Lancet Infectious Diseases
Volume
16
Issue
6
Type
Journal article
Categories
- Service delivery
Diseases
- Pneumococcal disease
Countries
- Gambia
Tags
- New vaccine introduction
WHO Regions
- African Region
